Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis

CNS Drugs

Volumn 25, Issue 2, 2011, Pages 157-169

  Castells, Xavier ^a,b   Ramos Quiroga, Josep Antoni ^a,c   Rigau, David ^d   Bosch, Rosa ^a   Nogueira, Mariana ^a   Vidal, Xavier ^c   Casas, Miguel ^a,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Iberoamerican Cochrane Centre   (Spain)

Author keywords

Adults; Attention deficit hyperactivity disorder; Meta analysis; Methylphenidate, therapeutic use

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 78951485584     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11539440-000000000-00000     Document Type: Article

References (60)

1. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004; 292: 619-23
2. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 2005; 47: 565-72
3. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792-8
4. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006; 36: 167-79
5. Young S, Toone B, Tyson C. Comorbidity and psychosocial profile in adults with attention deficit hyperactivity disorder. Pers Individ Diff 2003; 35: 743-55
6. Barkley RA, Gordon M. Research on comorbidity, adaptive functioning, and cognitive impairments in adults with ADHD: implication for a clinical practice. In: Goldstein S, Ellison AT, editors. Clinician's guide to adult ADHD: assessment and intervention. San Diego (CA): Academic Press, 2002: 43-69
7. Wilens TE. Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003; 63: 2395-411
8. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894-921
9. Maidment ID. Efficacy of stimulants in adult ADHD. Ann Pharmacother 2003; 37: 1884-90
10. Peterson K, McDonagh MS, Fu R. Comparative bene-fits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 2008; 197: 1-11
11. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2008; 23: 733-44
12. Meszaros A, Czobor P, Balint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 2009; 12: 1137-47
13. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127-52
14. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-9
15. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hy-peractivity disorder in children. Clin Pharmacol Ther 1999; 66: 295-305
16. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003; 17: 117-31
17. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008; 22: 603-11
18. Swanson J, Volkow N. Pharmacokinetic and pharmaco-dynamic properties of methylphenidate in humans. In: Solanto MV, Arnsten AFT, Castellanos FX, editors. Stimulant drugs and ADHD: basic and clinical neuroscience. New York: Oxford University Press, Inc., 2001: 259-82
19. Modi NB, Lindemulder B, Gupta SK. Single-and multiple-dose pharmacokinetics of an oralonce-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000; 40: 379-88
20. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002; 62: 2251-9
21. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7: 77-97
22. Dopfner M, Gerber WD, Banaschewski T, et al. Compara-tive efficacy of once-a-day extended-release methylpheni-date, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: I93-101
23. Jensen PS, Arnold LE, Swanson JM, et al. 3-Year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46: 989-1002
24. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: a randomized placebocontrolled double-blind cross-over trial. Psychol Med 2004; 34: 973-82
25. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-5
26. Davey Smith G, Egger M, Phillips AN. Meta-analysis: beyond the grand mean? BMJ 1997; 315: 1610-4
27. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006; 8: 4
28. Juni P, Altman DG, Egger M. Assessing the quality of clinical trials. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta analysis in context. London: BMJ Publishing Group, 2001: 87-108
29. Wender PH. Attention-deficit hyperactivity disorder in adults. New York: Oxford University Press, 1995
30. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131: 71-8
31. Ding YS, Gatley SJ, Thanos PK, et al. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 2004; 53: 168-75
32. Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 2008; 28 (3 Suppl. 2): S54-61
33. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
34. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008 [online]. Available from URL: http://www.cochranehandbook. org/[Accessed 2010 Jun 7]
35. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000; 19: 3127-31
36. Elbourne DR, Altman DG, Higgins JP, et al. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002; 31: 140-9
37. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29: 239-47
38. Biederman J, Mick E, Surman C, et al. A randomized, placebocontrolled trialof OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829-35
39. Bouffard R, Hechtman L, Minde K, et al. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 2003; 48: 546-54
40. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trialof methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 2005; 100: 1868-74
41. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol 1985; 8: 343-56
42. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: results of a double-blind, placebocontrolled crossover study. J Clin Psychiatry 2007; 68: 268-77
43. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13: 129-34
44. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 137-48
45. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 20-9
46. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41: 1059-63
47. Medori R, Ramos-Quiroga JA, Casas M, et al. A random-ized, placebocontrolled trialof three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63: 981-9
48. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebocontrolled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68: 93-101
49. Rosler M, Fischer R, Ammer R, et al. A randomised, placebocontrolled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259: 120-9
50. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebocontrolled trialof methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-94
51. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52: 434-43
52. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trialof methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 456-63
53. Spencer TJ, Adler LA, McGough JJ, et al., Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61: 1380-7
54. Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord 2002; 6: 49-60
55. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547-52
56. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006; 67 Suppl. 8: 38-45
57. Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 2007; 16 Suppl. 1: 45-54
58. Gonzalez MA, Pentikis HS, Anderl N, et al. Methylpheni-date bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002 Apr; 40 (4): 175-84
59. Markowitz JS, Straughn AB, Patrick KS, et al. Pharmaco-kinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 2003; 42 (4): 393-401
60. Reiz JL, Donnelly GA, Michalko K. Comparative bio-availability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. Clin Ther 2008; 30: 59-69